Religare Broking introduces investment in foreign equities

 Religare Broking introduces investment in foreign equities, collaborates with Vested Finance

Indian investors can now invest in the world’s biggest stock markets and create a
globally diversified portfolio

Religare Broking Ltd. through its partnership with Vested Finance has introduced foreign stock markets on its broking platform wherein clients can diversify their portfolio with international stocks. 1 million customers of Religare Broking can enjoy the benefits of geographical diversification and safeguard their portfolios from single currency risk. This partnership will enable investors to directly invest in US stocks that they consume on a regular basis including Apple, Amazon, Netflix, Facebook, etc. Vested Finance is an online investment platform that enables Indian investors to invest in the US stock market in a smooth and hassle-free manner.

Religare Broking Ltd. and Vested Finance will provide Indian investors exposure to the US stock market which captures over 50% of the global equity value via multiple investments instruments like stocks, ETFs, and curated investment portfolios called Vests. Investors can invest in fractional shares as low as USD1. The entire process involves digital on-boarding, commission-free investing, seamless USD deposits and easy withdrawals.

Vests are curated portfolios that allow investors to get started in an easy manner and this is a natural fit in Religare’s a renowned research-led platform. Through Vests, investors can invest in themes like SaaS, Digital Cash, All-Weather Portfolios, and across multiple asset classes depending on investors’ risk profile.

Announcing the partnership, Gurpreet Sidana, Chief Operating Officer, Religare Broking Ltd. said, "There is a clear interest and demand for international equities as Indian investors looking for avenues to diversify their portfolios and take advantage of the burgeoning international stock markets. Besides, we live in an age where investors are increasingly aware of global brands in exciting sectors including new-age businesses, technology and healthcare. With Vested, investors can also look at ready portfolios and research that can help them make an informed decision."

Speaking on the partnership, Viram Shah, Co-Founder & CEO, Vested Finance, said, “At Vested, we believe that global investing is truly a need rather than a choice and we are excited to partner with Religare to make the world’s largest market accessible to Indian investors. There is a growing awareness among Indian investors to diversify their portfolios internationally. It has never been easier to access the global markets from India. At Vested, our mission is to enable sustainable wealth creation by enabling these investors to go global.”

 

Following are some of the features of the offering:

         Zero commission - Unlimited transactions in US stocks with zero brokerage charges*

         Fractional investing - Ability to buy less than one share, enabling to invest as low as $1 for high priced shares such as Tesla, Apple, Amazon, Google, or Berkshire Hathaway

         Vests - Professionally curated portfolios of stocks and ETFs

         Simplified remittance process - Partnerships with banks to enable cost-effective fund transfers

         Investor support and safety – Assistance for the investors throughout the journey along with safety and security of the funds via SIPC and FDIC insurance

         Basic and Premium plans are offered by Religare Broking for investing through Vested Finance and the limited period offer has a discount voucher accordingly.

Laurus Labs registers revenue growth

 Laurus Labs registers revenue growth
of 31% and PAT Growth of 40%

Q1 FY22 Revenues up 31 %

Q1 FY22 EBITDA at ₹ 400 crs, up 41%, Margins at 31 %

Q1 FY22 PAT at ₹ 241 crs, up 40% Margins at 19 %

Chennai, July 29, 2021: Laurus Labs Ltd. (Laurus BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028), a leading research and development driven fully integrated pharmaceutical and biotech company in India announces its Q1 FY22 results.

 

Q1 FY22 Laurus reported:

• Total net revenue ₹ 1,279 crs, up 31% (Y-o-Y)
• EBITDA ₹  400 crs, up 41% (Y-o-Y)
• EBITDA margins at 31 %
• PAT at ₹ 241 Cr, up 40% (Y-o-Y)
• PAT margins at 19% (Y-o-Y)
• EPS (Diluted) for the period at  ₹ 4.5 per share (not annualised), up by 40.6 % (Y-o-Y)

 

Commenting on the results announcement, Dr. Satyanarayana Chava - CEO, said;

“We have started the financial year 22 with strong growth in FDF, with the strong demand in ARV’s for LMIC region and our portfolio expansion in developed markets. Our Synthesis business retained its growth momentum powered by the increased business from the existing clients and new clients; the segment registered strong growth with +95% YoY, with ongoing commercial supplies for four products. In the API segment, Oncology and ARV APIs registered healthy growth. In contrast, revenue from our other API witnessed a slowdown, and the growth is expected to restore from Q2 FY22, we remain confident of maintaining a growth trajectory in the Generic API business for FY22. In addition, Laurus Bio started contributing to the revenue and would add more from Q2 FY22, with the new fermentation capacities added in recombinant food protein.”

 

 

Commenting on the results announcement, V V Ravi Kumar, ED & Chief Financial Officer said;

“We are happy that Laurus Labs has registered revenue ₹ 1279 Crs in Q1 FY22, with 31% YoY. Our EBITDA margins were maintained at 31%. Laurus Bio has started contributing to revenues and margins from Q1 FY22. Our Gross Margins continue to grow on the back of a better product mix and improved sales from all the segments. Our performance focus is on growth driven by superior execution and completing our Future Ready strategy with manufacturing capacity expansions - a combination of brown and greenfield in API, FDF, and Synthesis divisions. With sustained business opportunities, we remain confident of achieving sustainable return ratios in the FY2022-23 and beyond.”

 

Business Highlights:

 

Overall

• Total Income at ₹ 1,279 Crs in Q1 FY22 growing by 31 % (Y-o-Y) Growth driven by sustained strong momentum across all business segments; particularly FDF and Synthesis
• R & D spent ₹ 49 Crs and 3.8 % of sales in Q1 FY22.

 

Generic FDF

• Recorded sale of ₹ 521 Crs: 41 % contribution in FY 22 Q1
• Validation completed for 4 products apart from filling of 28 ANDAs & NDAs in total.
• Capacity expansion is in progress

 

Generic API

• Filed 296 patents out of that 155 patents granted as of June 30, 2021
• Filed 66 DMFs
• Capacity expansion is in progress

Synthesis

• Total Number of Active Projects in the CDMO division stood at 50 as of 30^th June 2021.
• Commercial supplies ongoing for 4 products

Structurally Strong MSMEs set to Help Indian

Structurally Strong MSMEs set to Help Indian Economy Recover Under Emergency Credit Loan Guarantee Scheme

·         Research shows vast majority (over 80%) of MSMEs set to benefit from ECLGS considered structurally strong

 ·         When combined with portfolio management solutions, ECLGS gives lending institutions the ability to better manage portfolio risk and NPA losses

Chennai, 29 June, 2020: In its commitment to support India’s credit industry in refueling growth and managing asset quality, leading information and insights company TransUnion CIBIL has released an analysis on the Emergency Credit Line Guarantee Scheme (ECLGS) under the Atmanirbhar Bharat relief package.

The INR 3 lakh crores of expected credit infusion to the MSME segment is set to be completed by end of October 2020. The size of this package is significant when compared with 2.8 lakh crores of MSME credit disbursal in the full calendar year of 2019. The Guaranteed Emergency Credit Line (GECL) facility is applicable to all MSME borrowers with industry-wide aggregate credit exposure up to INR 25 crores and industry-wide delinquency less than or equal to 60 days as of 29th Feb. 2020.

Eligible MSMEs can borrow up to 20% of their aggregate credit exposure. The loans have four-year tenor with the first 12 months of principal covered under moratorium to further assist MSMEs benefitting from the scheme. Additionally, the loans provided under the GECL have a 100% credit guarantee and this makes it a huge opportunity for lenders to plan their lending policies strategically.

Assessing MSME credit risk to lend under the ECLGS

As part of its analysis, TransUnion CIBIL looked at the CIBIL MSME Rank (CIBIL Rank) as of 29^th Feb. 2020 for the MSMEs eligible under the ECLGS scheme. The CIBIL Rank distribution of eligible MSMEs in the ECLGS reveals that 81% belong to what is considered the structurally strong section of CIBIL Rank - CMR-6 or less. CIBIL Rank is a credit risk solution that uses machine learning algorithms to predict the probability of an MSME becoming a non-performing asset (NPA) in the next 12 months. CIBIL Rank assigns a rank on a scale of one to 10 to the MSME based on historical repayment behavior on its credit lines. CMR-1 is assigned to the least risky MSME and CMR-10 to the most risky MSME. The higher the CMR, the greater the risk of NPA associated with the MSME.

Speaking on the analysis findings, Mr. Rajesh Kumar, Managing Director and CEO of TransUnion CIBIL, said: “The ECLGS package is well structured scheme which not only provides the much needed access to funds for deserving MSMEs but also ensures long term stability of the portfolio quality of lending institutions. Credit institutions have a large and important role to play during these unprecedented times to help boost economic opportunities for deserving MSMEs and refuel the economy. ECLGS has set the stage for an accelerated credit infusion into the MSME sector. However, credit institutions have to adapt to the increasing requirements of monitoring MSME credit.”

Elaborating on the ECLGS analysis he added, “In addition to 100% credit guarantee, the fact that over 80% eligible MSMEs have a ranking of CMR-6 or better makes ECLGS guidelines inherently cater for risk containment. However, in the rapidly changing market conditions, the dynamics of MSME businesses are evolving every day and therefore it’s important to not only rely on original structural strength of MSME but to also regularly monitor borrower’s behavior.”

Distribution of ECLGS eligible MSMEs by CMR

Notes: Commercial loans classified on the basis of credit exposure aggregated at entity level, Micro: <1Cr; Small: ≥1Cr  & <10Cr; Medium1: ≥ 10Cr &  <25Cr; Super-Prime: CMR-1 to 3; Prime: CMR-4 to 6; Sub-Prime: CMR-7 to 10 MSMEs with aggregate credit exposure up to 25 crores and less than or equal to 60 days past due (DPD) are considered eligible under ECLGS scheme Finding and funding the good MSMEs under the Atmanirbhar Bharat relief package Finding and funding deserving businesses is critical to the recovery of the Indian economy and the ongoing financial health of the MSME sector. The study conducted in the recent MSME Pulse study makes the case that structurally strong MSMEs are better positioned to survive the current pandemic situation and emerge stable. These MSMEs are most deserving to receive financial assistance from credit institutions.

 

ECLGS has created an opportunity here for banks and financial institutions to identify and fund these entities and build a healthy portfolio. Such targeted interventions can help refuel the economy through these unprecedented times while ensuring that portfolio risk is under control. In order to proactively implement ECLGS for their MSME borrowers, the credit industry is partnering with TransUnion CIBIL to help implement the ECGLS guidelines and ensure astute lending and monitoring of portfolios under this scheme.

Speaking about the value of credit information insights in driving loans to MSMEs and business enterprises under this scheme, the MD & CEO of Union Bank, Mr. Rajkiran Rai, said: “Insights from TransUnion CIBIL have been supporting us in closely monitoring borrowers seeking and availing loans from multiple lenders and identify loan stacking behavior.”